Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

BACKGROUND: Telotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analogs. In TELESTAR and TELECAST phase III studies, patients with carcinoid syndrome received telotristat ethyl 250 or 500 mg 3 times per day (tid) or placebo tid in addition to somatosta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dillon, Joseph S., Kulke, Matthew H., Hörsch, Dieter, Anthony, Lowell B., Warner, Richard R. P., Bergsland, Emily, Welin, Staffan, O’Dorisio, Thomas M., Kunz, Pamela L., McKee, Chad, Lapuerta, Pablo, Banks, Phillip, Pavel, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714089/
https://www.ncbi.nlm.nih.gov/pubmed/32146619
http://dx.doi.org/10.1007/s12029-020-00375-2

Ejemplares similares

Ejemplares similares